| Effective drug combinations in breast, colon and pancreatic cancer cells P Jaaks, EA Coker, DJ Vis, O Edwards, EF Carpenter, SM Leto, L Dwane, ... Nature 603 (7899), 166-173, 2022 | 322 | 2022 |
| canSAR: an updated cancer research and drug discovery knowledgebase JE Tym, C Mitsopoulos, EA Coker, P Razaz, AC Schierz, AA Antolin, ... Nucleic acids research 44 (D1), D938-D943, 2016 | 111 | 2016 |
| canSAR: updated cancer research and drug discovery knowledgebase KC Bulusu, JE Tym, EA Coker, AC Schierz, B Al-Lazikani Nucleic acids research 42 (D1), D1040-D1047, 2014 | 105 | 2014 |
| canSAR: update to the cancer translational research and drug discovery knowledgebase C Mitsopoulos, P Di Micco, EV Fernandez, D Dolciami, E Holt, IL Mica, ... Nucleic acids research 49 (D1), D1074-D1082, 2021 | 96 | 2021 |
| Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens E Gonçalves, A Segura‐Cabrera, C Pacini, G Picco, FM Behan, P Jaaks, ... Molecular Systems Biology 16 (7), e9405, 2020 | 91 | 2020 |
| canSAR: update to the cancer translational research and drug discovery knowledgebase EA Coker, C Mitsopoulos, JE Tym, A Komianou, C Kannas, P Di Micco, ... Nucleic acids research 47 (D1), D917-D922, 2019 | 64 | 2019 |
| SLFN11 informs on standard of care and novel treatments in a wide range of cancer models C Winkler, J Armenia, GN Jones, L Tobalina, MJ Sale, T Petreus, T Baird, ... British journal of cancer 124 (5), 951-962, 2021 | 60 | 2021 |
| AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia SB Balachander, SW Criscione, KF Byth, J Cidado, A Adam, P Lewis, ... Clinical Cancer Research 26 (24), 6535-6549, 2020 | 57 | 2020 |
| AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors S Dunn, C Eberlein, J Yu, A Gris-Oliver, SH Ong, U Yelland, N Cureton, ... Oncogene 41 (46), 5046-5060, 2022 | 20 | 2022 |
| AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor … V Flemington, EJ Davies, D Robinson, LC Sandin, O Delpuech, P Zhang, ... Molecular cancer therapeutics 20 (2), 238-249, 2021 | 19 | 2021 |
| Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers A Stewart, EA Coker, S Pölsterl, A Georgiou, AR Minchom, S Carreira, ... Molecular cancer therapeutics 18 (8), 1396-1404, 2019 | 18 | 2019 |
| Large-scale pan-cancer cell line screening identifies actionable and effective drug combinations AC Bashi, EA Coker, KC Bulusu, P Jaaks, C Crafter, H Lightfoot, M Milo, ... Cancer discovery 14 (5), 846-865, 2024 | 12 | 2024 |
| Individualized prediction of drug response and rational combination therapy in NSCLC using artificial intelligence–enabled studies of acute phosphoproteomic changes EA Coker, A Stewart, B Ozer, A Minchom, L Pickard, R Ruddle, S Carreira, ... Molecular cancer therapeutics 21 (6), 1020-1029, 2022 | 11 | 2022 |
| SiGNet: A signaling network data simulator to enable signaling network inference EA Coker, C Mitsopoulos, P Workman, B Al-Lazikani Plos one 12 (5), e0177701, 2017 | 6 | 2017 |
| Leveraging human genetics to guide cancer drug development B Kinnersley, A Sud, EA Coker, JE Tym, P Di Micco, B Al-Lazikani, ... JCO clinical cancer informatics 2, 1-11, 2018 | 5 | 2018 |
| A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level DJ Vis, P Jaaks, N Aben, EA Coker, S Barthorpe, A Beck, C Hall, J Hall, ... Cell Reports Medicine 5 (8), 2024 | 3 | 2024 |
| Simulated ablation for detection of cells impacting paracrine signalling in histology analysis JP Taylor–King, E Baratchart, A Dhawan, EA Coker, IH Rye, H Russnes, ... Mathematical Medicine and Biology: a Journal of the IMA 36 (1), 93-112, 2019 | 2 | 2019 |
| Abstract B096: canSAR, a cancer research and drug discovery knowledgebase EA Coker, P Di Micco, JE Tym, C Mitsopoulos, A Komianou, AA Antolin, ... Molecular Cancer Therapeutics 17 (1_Supplement), B096-B096, 2018 | 2 | 2018 |
| AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER E Coker, A Emery, M Garnett, P Jaaks, H Lightfoot, JD Santos, D Vis, ... US Patent App. 18/836,940, 2025 | | 2025 |
| Large scale pan cancer drug combination screening to identify effective and actionable combinations and biomarker hypothesis A Bashi, EA Coker, K Bulusu, M Milo, C Crafter, J Lynch, D Jenkins, ... Cancer Research 83 (7_Supplement), 5321-5321, 2023 | | 2023 |
Bissan Al-LazikaniProfessor, Genomic Medicine; Director Therapeutics Data Scienceยืนยันอีเมลแล้วที่ mdanderson.org